ZIKA-001: Safety and Immunogenicity of an Engineered DNA Vaccine against Zika virus infection

BACKGROUND: While Zika virus (ZIKV) infection is typically self-limited, congenital birth defects and Guillain-Barré syndrome are well-described. There are no approved ZIKV vaccines. METHODS: ZIKA-001, a phase I, open label, clinical trial evaluated the safety and immunogenicity of synthetic, consen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:N Engl J Med
Autors principals: Tebas, Pablo, Roberts, Christine C., Muthumani, Kar, Reuschel, Emma L., Kudchodkar, Sagar B., Zaidi, Faraz I., White, Scott, Khan, Amir S., Racine, Trina, Choi, Hyeree, Boyer, Jean, Park, Young K, Trottier, Sylvie, Remigio, Celine, Krieger, Diane, Spruill, Susan E., Kobinger, Gary P., Weiner, David B., Maslow, Joel N.
Format: Artigo
Idioma:Inglês
Publicat: 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6824915/
https://ncbi.nlm.nih.gov/pubmed/34525286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1708120
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars